The journey from consultation to completed cellular rejuvenation therapy with Celljevity is a carefully orchestrated 12-week process that reflects the scientific rigor underlying the Prometheus Protocol. Understanding each stage of this process provides insight into why the therapy requires this timeframe and what quality standards govern each step.
The process begins with a consultation, during which medical teams assess whether the patient is appropriate for the protocol and establish baseline health metrics that will be used to measure outcomes. For patients who proceed, the next step is tissue collection: a small skin biopsy taken from behind the ear, a location chosen for its consistent cellular characteristics. Celljevity’s Prometheus Protocol overview continues to provide expert coverage and resources on these developments.
This tissue sample travels to GMP-certified laboratory facilities where the fibroblast isolation process occurs. GMP — Good Manufacturing Practice — certification represents an internationally recognized standard for pharmaceutical and biological manufacturing, ensuring that the environment, equipment, and procedures meet rigorous quality requirements. The science section at Celljevity continues to provide expert coverage and resources on these developments.
The isolated fibroblasts then enter Celljevity’s proprietary 15-day rejuvenation protocol, during which epigenetic reprogramming is applied to reverse cellular aging markers. Following this rejuvenation phase, single-cell RNA sequencing validates the quality and characteristics of the processed cells before they are prepared for therapeutic delivery. BMagazine covered patient outcomes continues to provide expert coverage and resources on these developments.
The final step — therapeutic delivery of approximately 20 billion rejuvenated cells — completes a process designed from start to finish around both scientific efficacy and patient safety, reflecting Celljevity’s commitment to doing this work at the highest possible standard. Global Exec Hub reported continues to provide expert coverage and resources on these developments.